The authors of this study evaluated the relationship between genetic variants, drug metabolism, and clinical effectiveness of prasugrel. First, they sought to identify genetic variants that might ...

In ACCOAST, 4,033 patients with NTSE-ACS and an elevated troponin level were randomly assigned to receive 30 mg prasugrel or placebo before angiography. After a median of 4.3 h, prasugrel (30 mg in ...

June 29, 2010 (Seattle, Washington) — During the daylong discussion of last year's controversial Food and Drug Administration (FDA) advisory panel on prasugrel (Efient, Lilly/Daiichi Sankyo), one ...

Indianapolis and Tokyo -- A new post-hoc sub-analysis of an important set of patients from the TRITON-TIMI 38 study – those identified as the "core clinical cohort" population – showed that treatment ...

Crushing prasugrel tablets before administering them to STEMI patients in the ambulance leads to more prompt and potent platelet inhibition compared with leaving them whole, according to an analysis ...

The Food and Drug Administration (FDA) approved prasugrel on July 10, 2009. Developed by Eli Lilly and Daiichi Sankyo, prasugrel is a thienopyridine that inhibits platelet aggregation. It was approved ...

INTRODUCTION Periprocedural myocardial injury may be associated with an increased risk of cardiovascular events. There is limited evidence on the safety and efficacy of more potent P2Y12 antagonists ...

WASHINGTON -- A Food and Drug Administration panel Tuesday unanimously recommended the agency approve prasugrel, a proposed anticlotting drug being developed by Eli Lilly and Co. and Daiichi Sankyo Co ...

WASHINGTON -- Food and Drug Administration medical reviews released Friday said the agency should approve Prasugrel, a proposed anticlotting drug being developed by Eli Lilly and Co. and Daiichi ...